ClinicalTrials.gg
RecruitingNCT06995183IMAGE-LPAUpdated May 29, 2025

Heart CT Imaging to Detect Early Coronary Artery Disease in First-Degree Relatives With High or Low Lipoprotein(a) Identified Through Family Screening

An observational study in Lipoprotein(a), sponsored by E.S.stroes. Recruiting at 1 site in Netherlands. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by E.S.stroes · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Coronary Artery Disease with a site in Netherlands — 44 open to participants now, 66 under way, 5 of them phase 3. Coronary Artery Disease · Netherlands.

Planned enrollment
66th of 84
150 · median 598
Started
2025
with 6 others
Observational
84 of 283
19 open now
Primary completion
2026-12
later than 36 of 65 live
Registered
271st of 283
by date

Among the 283 studies in Coronary Artery Disease with a site in Netherlands, this one is the 66th largest by planned enrollment of the 84 observational ones that give a count, is one of 7 that started in 2025, is one of 84 observational ones, reaches primary completion later than 36 of the 65 other live ones, and was the 271st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

44 of the 283 studies in Coronary Artery Disease with a site in Netherlands are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 50 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Coronary Artery Disease with a site in Netherlands, or all of them as a file.
02

Study summary

Lipoprotein(a), or Lp(a), is a type of cholesterol that can increase the risk of heart and blood vessel disease. Many people are unaware they have high Lp(a), since it is not routinely measured and usually causes no symptoms on its own. However, elevated Lp(a) levels tend to run in families, meaning that close relatives of individuals with high Lp(a) are more likely to have it as well.

At Amsterdam UMC, family members of patients with high Lp(a) are invited for cascade screening, which includes testing for Lp(a) and other cardiovascular risk factors. From this screened group, a selection of individuals with either high or low Lp(a) levels are invited to participate in the IMAGE-LPA study.

In IMAGE-LPA, participants undergo a comprehensive cardiovascular evaluation, including blood tests and heart imaging using CT scans. Two types of scans are performed: (1) a calcium score scan to detect early calcium buildup in the heart's arteries (an early marker of atherosclerosis), and (2) coronary CT angiography to assess for plaque and narrowing in the coronary arteries.

The goal of the study is to compare individuals with high versus low Lp(a) identified through cascade screening, to determine whether high Lp(a) levels are associated with early signs of heart disease in this patient group.

The study does not involve any medications or invasive procedures. The findings may help clarify whether heart imaging can improve early detection in individuals with high Lp(a), and guide future strategies for preventing cardiovascular disease in families affected by this inherited risk factor.

03

Conditions studied

  • Lipoprotein(a)

Keywords

  • Lipoprotein(a)
  • coronary atherosclerosis
  • subclinical atherosclerosis
  • coronary artery calcium scoring
  • coronary computed tomography angiography
  • cardiovascular risk assessment
  • primary prevention
  • coronary artery disease
  • cascade screening
  • imaging biomarkers
  • atherosclerotic cardiovascular disease
  • lipid disorders
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Participants will be selected from first-degree relatives of patients with elevated Lipoprotein(a) who previously participated in the Lp(a) familial cascade screening program at the Amsterdam UMC Vascular Medicine outpatient clinic. All participants have been screened for Lp(a) levels as part of routine clinical care and have indicated willingness to be contacted for future research. Eligible individuals are middle-aged or older and have no history of clinically manifest atherosclerotic cardiovascular disease.

Eligibility criteria

In order to be eligible to participate in this study in the elevated Lp(a) subgroup, a subject must meet all of the following inclusion criteria:

  • Man or woman ≥50 years of age;
  • Lp(a) level ≥ 150 nmol/L;
  • Identified as having elevated Lp(a) through Lp(a) family cascade screening at the Amsterdam UMC Vascular Medicine outpatient clinic;
  • Able and willing to provide ;
  • Able to comply with study requirements.

In order to be eligible to participate in this study in the Low Lp(a) subgroup, a subject must meet all of the following inclusion criteria:

  • Man or woman ≥50 years of age;
  • Lp(a) level \< 50 nmol/L;
  • Identified as having elevated Lp(a) through Lp(a) family cascade screening at the Amsterdam UMC Vascular Medicine outpatient clinic;
  • Able and willing to provide informed consent;
  • Able to comply with study requirements.

A potential subject who meets any of the following criteria will be excluded from participation in this study (both subgroups):

  • Renal insufficiency, defined as \< 30 ml/min
  • History of ASCVD (acute coronary syndrome, history of myocardial infarction, stable or unstable angina pectoris or coronary or other arterial revascularization, stroke, or peripheral artery disease including aortic aneurysm, all of atherosclerotic origin)
  • History of atrial fibrillation
  • Prior and current use of statins
  • Any other treatment or condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
  • Unable or unwilling to provide informed consent
  • Unable to comply with study requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • High Lp(a)

    Individuals aged 50 years or older who were identified with elevated Lipoprotein(a) levels (≥150 nmol/L) through familial cascade screening at the Amsterdam UMC Vascular Medicine outpatient clinic. These participants have no history of clinical atherosclerotic cardiovascular disease and are undergoing imaging to assess subclinical coronary atherosclerosis.

  • Low Lp(a)

    Age- and sex-matched individuals aged 50 years or older with normal Lipoprotein(a) levels (\<50 nmol/L), identified through the same familial cascade screening program. These participants also have no history of clinical atherosclerotic cardiovascular disease and serve as controls to compare the prevalence of subclinical coronary plaque.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Coronary Atherosclerotic Plaque Detected on CCTA

    Assessment of the presence or absence of any coronary artery plaque as detected by coronary computed tomography angiography (CCTA). Plaque is defined as within and/or adjacent to the vessel lumen distinguishable from the lumen and surrounding tissue.

    Time frame: Day 1

Secondary outcomes

  1. Number of Participants with Obstructive Coronary Stenosis (≥50% Luminal Narrowing) on CCTA

    Measured by CCTA. Obstructive stenosis is defined as luminal narrowing of ≥50% in any major coronary artery, based on visual assessment and automated quantification.

    Time frame: Day 1

  2. Total Coronary Plaque Volume

    Total plaque volume (in mm³) across all coronary segments, quantified using FDA-approved software (Cleerly Inc.) from CCTA scans. Includes both calcified and non-calcified plaque.

    Time frame: Day 1

  3. Calcified and Non-Calcified Plaque Volumes

    Volumes (in mm³) of calcified and non-calcified coronary plaque separately measured using semi-automated quantification of CCTA images. Non-calcified plaque includes fibrous and lipid-rich components.

    Time frame: Day 1

  4. Low-Attenuation Plaque Volume

    Volume (in mm³) of coronary plaque with CT attenuation \<30 HU, measured on CCTA. Low-attenuation plaque is associated with high-risk morphology and vulnerability.

    Time frame: Day 1

  5. Pericoronary Adipose Tissue (PCAT) Attenuation

    Mean CT attenuation (in Hounsfield Units) of adipose tissue surrounding coronary arteries, as a surrogate of coronary inflammation. Measured on CCTA at the proximal right coronary artery.

    Time frame: Day 1

  6. Number of High-Risk Plaque Features

    CCTA-based count of high-risk plaque features per patient, including positive remodeling, napkin-ring sign, low-attenuation plaque, and spotty calcification. A higher count suggests greater risk of future events.

    Time frame: Day 1

  7. Coronary Artery Calcium (CAC) Score

    Agatston CAC score obtained from non-contrast CT scan preceding CCTA. Score quantifies coronary calcification. Scale: 0-400+; higher score = more calcification, worse outcome

    Time frame: Day 1

  8. CAD-RADS Classification

    Coronary Artery Disease Reporting and Data System (CAD-RADS) score, a standardized grading system for coronary stenosis severity based on CCTA. Scores range from 0 (no plaque) to 5 (severe stenosis ≥70%).

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Annink ME, Janssen ES, Reeskamp LF. Effectiveness of cascade screening for elevated lipoprotein(a), an underdiagnosed family disorder. Curr Opin Lipidol. 2024 Dec 1;35(6):290-296. doi: 10.1097/MOL.0000000000000951. Epub 2024 Sep 18. PubMed 39259684 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because participants did not provide explicit consent for their data to be shared beyond the scope of the approved study. Data sharing was not included as part of the informed consent process.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 18 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 29, 2025
StartEst.
Jun 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06995183
Lead sponsor
E.S.stroes
Responsible party
E.S.stroes (Prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Sponsor-investigator
First posted
May 29, 2025
Start date
Jun 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 29, 2025

Study contacts

Maxim E Annink, MD MSc LLM
Contact
m.e.annink@amsterdamumc.nl
+31205669111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion